However, the Hsp90 inhibitor pimitespib has successfully reached clinical practice in Japan for the treatment of advanced gastrointestinal stromal tumor, confirming Hsp90 as a clinically relevant target for cancer treatment [19,25]. This evidence concerns the gene HSP90AA1 and cancer.